Effect of Pioglitazone in Preventing In-Stent Restenosis After Percutaneous Coronary Intervention in Patients with Type 2 Diabetes: A Meta-Analysis

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2016 May 11

PMID 27163676

Citations 6

Authors

Shi-Jie Zhao

Zhao-Shuang Zhong

Guo-Xian Qi

Li-Ye Shi

Ling Chen

Wen Tian

Affiliations

Soon will be listed here.

Abstract

Background: The benefits of pioglitazone in patients with type 2 diabetes mellitus (T2DM) after percutaneous coronary intervention (PCI) is unclear.

Objectives: To evaluate the effect of pioglitazone on prevention of in-stent restenosis (ISR) in patients with T2DM after PCI.

Methods: All full-text published relevant studies compared the effect of pioglitazone with control group (placebo or no pioglitazone treatment) on ISR in patients with T2DM after PCI were identified by searching the databases including PubMed, EMBASE, Cochrane Library and ISI Web of Science through October 2015. The endpoints were defined as the rate of ISR, late lumen loss, in-stent neointimal volume, target lesion revascularization (TLR) and major adverse cardiac events (MACE).

Results: Six studies (5 RCTs and 1 retrospective study), comprising 503 patients, were included into this meta-analysis. In the pioglitazone group, as compared with the control group, the risk ratio for ISR was 0.48 (I2 = 14.5%, P = 0.322; 95%CI 0.35 to 0.68, P<0.001), the risk ratio for TLR was 0.58 (I2 = 6.0%, P = 0.363; 95%CI 0.38 to 0.87, P = 0.009). The result showed there was no association between the use of pioglitazone and the events of MACE (I2 = 36.7%, P = 0.209; RR 0.56, 95%CI 0.30 to 1.05, P = 0.071). For the considerable heterogeneity, further analysis was not suitable for the endpoints of late lumen loss (I2 = 81.9%, P<0.001) and neointimal volume (I2 = 75.9%, P = 0.016).

Conclusions: The treatment of pioglitazone was associated with a reduction in ISR and TLR in T2DM patients suffering from PCI, except the incidence of MACE.

Citing Articles

Treatment Effects in Randomized and Nonrandomized Studies of Pharmacological Interventions: A Meta-Analysis.

Salcher-Konrad M, Nguyen M, Savovic J, Higgins J, Naci H JAMA Netw Open. 2024; 7(9):e2436230.

PMID: 39331390 PMC: 11437387. DOI: 10.1001/jamanetworkopen.2024.36230.

Diabetes and restenosis.

Wilson S, Mone P, Kansakar U, Jankauskas S, Donkor K, Adebayo A Cardiovasc Diabetol. 2022; 21(1):23.

PMID: 35164744 PMC: 8845371. DOI: 10.1186/s12933-022-01460-5.

Rethinking pioglitazone as a cardioprotective agent: a new perspective on an overlooked drug.

Nesti L, Trico D, Mengozzi A, Natali A Cardiovasc Diabetol. 2021; 20(1):109.

PMID: 34006325 PMC: 8130304. DOI: 10.1186/s12933-021-01294-7.

Pioglitazone Is Associated with Lower Major Adverse Cardiovascular and Cerebrovascular Events than DPP4-Inhibitors in Diabetic Patients with End-Stage Renal Disease: A Taiwan Nationwide Cohort Study, 2006-2016.

Lin M, Yang H, Yen C, Wu C, Jenq C, Kuo G J Clin Med. 2020; 9(11).

PMID: 33172034 PMC: 7694655. DOI: 10.3390/jcm9113578.

Effect of pioglitazone on cardiometabolic profiles and safety in patients with type 2 diabetes undergoing percutaneous coronary artery intervention: a prospective, multicenter, randomized trial.

Tanaka A, Komukai S, Shibata Y, Yokoi H, Iwasaki Y, Kawasaki T Heart Vessels. 2018; 33(9):965-977.

PMID: 29487991 DOI: 10.1007/s00380-018-1143-3.

References

Hong S, Kim M, Cha K, Park H, Chae S, Hur S . Comparison of three-year clinical outcomes between sirolimus-versus paclitaxel-eluting stents in diabetic patients: prospective randomized multicenter trial. Catheter Cardiovasc Interv. 2010; 76(7):924-33. DOI: 10.1002/ccd.22369. View

Mizoguchi M, Tahara N, Tahara A, Nitta Y, Kodama N, Oba T . Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta. JACC Cardiovasc Imaging. 2011; 4(10):1110-8. DOI: 10.1016/j.jcmg.2011.08.007. View

Guerra E, Byrne R, Kastrati A . Pharmacological inhibition of coronary restenosis: systemic and local approaches. Expert Opin Pharmacother. 2014; 15(15):2155-71. DOI: 10.1517/14656566.2014.948844. View

Nissen S, Wolski K . Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007; 356(24):2457-71. DOI: 10.1056/NEJMoa072761. View

Moussa I, Leon M, Baim D, ONeill W, Popma J, Buchbinder M . Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation. 2004; 109(19):2273-8. DOI: 10.1161/01.CIR.0000129767.45513.71. View

Cheang W, Fang X, Tian X . Pleiotropic effects of peroxisome proliferator-activated receptor γ and δ in vascular diseases. Circ J. 2013; 77(11):2664-71. DOI: 10.1253/circj.cj-13-0647. View

Yokoyama J, Sutoh N, Higuma T, Horiuchi D, Katoh C, Yokota T . Efficacy and safety of low-dose pioglitazone after primary coronary angioplasty with the use of bare metal stent in patients with acute myocardial infarction and with type 2 diabetes mellitus or impaired glucose tolerance. Heart Vessels. 2007; 22(3):146-51. DOI: 10.1007/s00380-006-0951-z. View

Oremus M, Wolfson C, Perrault A, Demers L, Momoli F, Moride Y . Interrater reliability of the modified Jadad quality scale for systematic reviews of Alzheimer's disease drug trials. Dement Geriatr Cogn Disord. 2001; 12(3):232-6. DOI: 10.1159/000051263. View

Yang T, Park S, Hong M, Park D, Park K, Kim Y . Impact of diabetes mellitus on angiographic and clinical outcomes in the drug-eluting stents era. Am J Cardiol. 2005; 96(10):1389-92. DOI: 10.1016/j.amjcard.2005.07.043. View

10.

Woods T, Marks A . Drug-eluting stents. Annu Rev Med. 2004; 55:169-78. DOI: 10.1146/annurev.med.55.091902.105243. View

11.

Nishio K, Sakurai M, Kusuyama T, Shigemitsu M, Fukui T, Kawamura K . A randomized comparison of pioglitazone to inhibit restenosis after coronary stenting in patients with type 2 diabetes. Diabetes Care. 2005; 29(1):101-6. DOI: 10.2337/diacare.29.01.06.dc05-1170. View

12.

Takagi T, Yamamuro A, Tamita K, Yamabe K, Katayama M, Mizoguchi S . Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study. Am Heart J. 2003; 146(2):E5. DOI: 10.1016/S0002-8703(03)00146-7. View

13.

Goldberg R, Kendall D, Deeg M, Buse J, Zagar A, Pinaire J . A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 2005; 28(7):1547-54. DOI: 10.2337/diacare.28.7.1547. View

14.

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009; 151(4):264-9, W64. DOI: 10.7326/0003-4819-151-4-200908180-00135. View

15.

Hong S, Kim M, Ahn T, Ahn Y, Bae J, Shim W . Multiple predictors of coronary restenosis after drug-eluting stent implantation in patients with diabetes. Heart. 2006; 92(8):1119-24. PMC: 1861125. DOI: 10.1136/hrt.2005.075960. View

16.

Kornowski R, Hong M, Tio F, Bramwell O, Wu H, Leon M . In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol. 1998; 31(1):224-30. DOI: 10.1016/s0735-1097(97)00450-6. View

17.

Abizaid A, Kornowski R, Mintz G, Hong M, Abizaid A, Mehran R . The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. J Am Coll Cardiol. 1998; 32(3):584-9. DOI: 10.1016/s0735-1097(98)00286-1. View

18.

Delhaye C, Maluenda G, Wakabayashi K, Ben-Dor I, Lemesle G, Collins S . Long-term prognostic value of preprocedural C-reactive protein after drug-eluting stent implantation. Am J Cardiol. 2010; 105(6):826-32. DOI: 10.1016/j.amjcard.2009.10.064. View

19.

Hong S, Kim S, Kim T, Kim E, Ahn C, Park J . Cellular and molecular changes associated with inhibitory effect of pioglitazone on neointimal growth in patients with type 2 diabetes after zotarolimus-eluting stent implantation. Arterioscler Thromb Vasc Biol. 2010; 30(12):2655-65. DOI: 10.1161/ATVBAHA.110.212670. View

20.

Kasai T, Miyauchi K, Yokoyama T, Kajimoto K, Sumiyoshi K, Kubota N . Pioglitazone attenuates neointimal thickening via suppression of the early inflammatory response in a porcine coronary after stenting. Atherosclerosis. 2007; 197(2):612-9. DOI: 10.1016/j.atherosclerosis.2007.08.030. View